In addition to breast cancer and ovarian cancer, there are also several clinical trials on PARP inhibitors for BRCA1/2- or ATM- mutant patients with prostate cancer [19] or cervical cancer [NCT04641728]. Here, BRCA1 is linked to ovarian carcinoma.